Benzinga
Benzinga
Noticias de España
Acciones
Índices
Bonos
ETFs
Economía
General
Noticias de EE.UU.
Acciones
Índices
Ganancias
Economía
Mercados de predicción
Mercados privados
Otros mercados
Calificaciones de analistas
Trading
Comunicados de prensa
Noticias Mundiales
Europa
Asia
Latinoamérica
Criptomonedas
Noticias
Altcoins
Bitcoin
Blockchain
Dogecoin
Ethereum
Shiba Inu
NFT
Formación
Invertir en criptomonedas
Invertir en acciones
Forex
Benzinga
domingo, octubre 25
Noticias de España
Acciones
Índices
Bonos
ETFs
Economía
General
Noticias de EE.UU.
Acciones
Índices
Ganancias
Economía
Mercados de predicción
Mercados privados
Otros mercados
Calificaciones de analistas
Trading
Comunicados de prensa
Noticias Mundiales
Europa
Asia
Latinoamérica
Criptomonedas
Noticias
Altcoins
Bitcoin
Blockchain
Dogecoin
Ethereum
Shiba Inu
NFT
Formación
Invertir en criptomonedas
Invertir en acciones
Forex
ImmunityBio Inc
IBRX
NASDAQ
Lista de seguimiento
Get Report
Trade with Public
Get Report
Trade with Public
$8.22
-0.09
-1.08%
Últ. Act.: Oct 23, 7:37 PM
Get Report
Panorámica general
Noticias
Previsión de beneficios
Eventos
Precios objetivo
Finanzas
Sentimiento
Propiedad
Comparar
Opciones
Informe de acciones
ImmunityBio Financials
ImmunityBio (IBRX) financial statements — income, revenue, gross margin and key metrics.
Earnings & Guidance News
PRO
ImmunityBio Q2 Adj. EPS $(0.08) Beats $(0.09) Estimate, Sales $51.240M Beat $49.700M Estimate
ImmunityBio (NASDAQ:IBRX) reported quarterly losses of $(0.08) per share which beat the analyst consensus estimate of $(0.09) by 11.11 percent. This is a 20 percent increase over losses of $(0.10) per share from the
Benzinga Newsdesk
ImmunityBio Stock Drops After Earnings Miss Despite Anktiva Momentum
ImmunityBio shares fall after Q1 losses misses estimates despite strong ANKTIVA sales growth and updated bladder cancer treatment guidelines.
Vandana Singh
PRO
UPDATE: ImmunityBio Q1 Adj. EPS $(0.08) Misses $(0.07) Estimate, Sales $44.206M Beat $43.069M Estimate
ImmunityBio (NASDAQ:IBRX) reported quarterly losses of $(0.08) per share which missed the analyst consensus estimate of $(0.07) by 14.29 percent. This is a 20 percent increase over losses of $(0.10) per share from the
Benzinga Newsdesk
PRO
ImmunityBio Q1 EPS $(0.62) Misses $(0.07) Estimate, Sales $44.206M Beat $43.069M Estimate
ImmunityBio (NASDAQ:IBRX) reported quarterly losses of $(0.62) per share which missed the analyst consensus estimate of $(0.07) by 785.71 percent. This is a 313.33 percent decrease over losses of $(0.15) per share from
Benzinga Newsdesk
Why Is ImmunityBio Stock Rallying Thursday?
ImmunityBio stock rises as Q1 revenue jumps 168% and Anktiva adoption grows, even as FDA warning prompts review of promotional claims.
Vandana Singh
ImmunityBio Supersedes Expectations With Fivefold Revenue Increase
ImmunityBio stock climbs after Anktiva sales surge 750%, revenue beats estimates, and new Saudi partnership fuels growth.
Vandana Singh
